• Evinacumab shows promise in severe hypertriglyceridemia trial europeanpharmaceuticalreview
    May 18, 2021
    The investigational antibody evinacumab was able to lower triglycerides by up to 82 percent in severe hypertriglyceridemia patients with acute pancreatitis.
  • FDA Approves Evkeeza americanpharmaceuticalreview
    February 22, 2021
    Regeneron Pharmaceuticals announced the U.S. Food and Drug Administration (FDA) approved EvkeezaTM (evinacumab-dgnb) as an adjunct to other low-density lipoprotein cholesterol (LDL-C) lowering therapies to treat adult and pediatric patients aged 12 ...
PharmaSources Customer Service